Bone Density and Circulating Mediators of Bone Metabolism in Chronic SCI
Bone Density and Circulating Mediators of Bone Metabolism in Chronic SCI
批准号:
7450233
负责人:
Leslie R. Morse
金额:
$21.19万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2010-03-31
关键词:
AffectAgeAlcohol consumptionAppendixAutonomic DysreflexiaBiological MarkersBiologyBloodBone DensityBone ResorptionBostonC-telopeptideCerebral PalsyChronicClinicalClinical TrialsConditionDataDecubitus ulcerDevelopmentDiagnosisDiseaseDistalEnrollmentFemurFractureFutureHealthHealth behaviorHip region structureHypertensive CrisisIndividualInjuryInterventionKneeLeftLesionMeasuresMediator of activation proteinMetaphysisMineralsNatural HistoryNervous System TraumaNeurologicOsteocalcinOsteoclastsOsteomyelitisOsteoporosisParalysedParticipantPathogenesisPathway interactionsPatientsPatternPersonsPopulationPostmenopausal OsteoporosisPreventionProcessProspective StudiesProtocols documentationPublic HealthQuadriplegiaRangeRateRecombinantsRiskScanningScreening procedureSecondary toSerumSeveritiesSeverity of illnessSiteSkeletal systemSmokingSpinal cord injuryStrokeTNFSF11 geneTestingTherapeuticThinkingTraumaTreatment EfficacyTreatment ProtocolsTumor necrosis factor receptor 11bVertebral columnWorkbasebonebone lossbone metabolismbone turnoverdisabilityimprovedinsightmedical complicationprogramsresponsetherapeutic targettibia
中文摘要
描述(由申请人提供):脊髓损伤(SCI)后发生过度骨质流失,导致骨质疏松症和骨折风险增加。虽然这种骨质流失的潜在原因尚不清楚,但其严重程度和模式与其他已知的骨质疏松症原因(包括停用和绝经后骨质疏松症)不同。目前,人们对这种骨质流失的原因或导致其严重程度的自然历史和具体因素知之甚少。根据初步研究,我们假设骨保护标志物骨保护素(OPG)参与了sci诱导的骨质流失的发病机制,可能是该人群疾病严重程度和骨折风险的生物标志物。此外,如果得到证实,OPG是预防和治疗神经源性骨质流失的潜在强有力的治疗靶点。
英文摘要
DESCRIPTION (provided by applicant): Excessive bone loss occurs following spinal cord injury (SCI) leading to osteoporosis and an increased risk of fracture. While the underlying cause of this bone loss remains to be clarified, it is distinct in severity and pattern from other known causes of osteoporosis including disuse and postmenopausal osteoporosis. Currently, little is known about the cause of this bone loss or the natural history and specific factors that contribute to its severity. Based on preliminary studies, we hypothesize the osteoprotective marker osteoprotegerin (OPG) is involved in the pathogenesis of SCI-induced bone loss and may be a biomarker of disease severity and fracture risk in this population. Furthermore, if confirmed, OPG is a potentially powerful therapeutic target in the prevention and treatment of neurogenic bone loss.
In this exploratory and developmental program, we propose to investigate differences in bone mineral density in individuals with tetraplegia and in those with lesser degrees of SCI. We will determine the relationship between bone mineral density at sites below the neurological lesion and circulating levels of OPG. Participants with SCI whose health behaviors (smoking, alcohol use) and comorbid illnesses are known due to enrollment in a longitudinal health study at VA Boston will be studied. As osteoporosis is prevalent in this patient population but currently under-treated, we expect to contribute to the understanding of this disease process for the development of improved clinical interventions. Furthermore, this work will contribute to the understanding of bone loss following neurological injury and will have broader health implications for health conditions ranging from stroke to cerebral palsy.
PUBLIC HEALTH RELEVANCE: This project seeks to understand bone loss triggered by spinal cord injury. A rapid, severe bone loss occurs after the spinal cord injury leaving the bones brittle and easy to fracture. This bone loss is not well understood. But, it appears to be different from bone loss seen with aging in that it affects the knees more than the hips and spine.
We believe the degree of paralysis is the most important factor in determining how much bone is lost following spinal cord injury. We will test this hypothesis by determining bone density in subjects with more severe injury and those with less severe injury. We will also test the hypothesis that neurological injury causes a deficiency of a molecule in the blood known to protect bone density. We believe individuals with the most severe form of paralysis will have lower levels of this molecule (osteoprotegerin or OPG) and lower bone mineral density.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Adiposity and Bone Loss in Spinal Cord Injury
-
批准号:7867329
-
项目类别:
-
资助金额:$66.94万
-
财政年份:2010
-
负责人:Leslie R. Morse
-
依托单位:
Adiposity and Bone Loss in Spinal Cord Injury
-
批准号:8653535
-
项目类别:
-
资助金额:$55.61万
-
财政年份:2010
-
负责人:Leslie R. Morse
-
依托单位:
Adiposity and Bone Loss in Spinal Cord Injury
-
批准号:8456134
-
项目类别:
-
资助金额:$57.22万
-
财政年份:2010
-
负责人:Leslie R. Morse
-
依托单位:
Adiposity and Bone Loss in Spinal Cord Injury
-
批准号:8247849
-
项目类别:
-
资助金额:$61.4万
-
财政年份:2010
-
负责人:Leslie R. Morse
-
依托单位:
Adiposity and Bone Loss in Spinal Cord Injury
-
批准号:8056504
-
项目类别:
-
资助金额:$61.38万
-
财政年份:2010
-
负责人:Leslie R. Morse
-
依托单位:
Bone Density and Circulating Mediators of Bone Metabolism in Chronic SCI
-
批准号:7935766
-
项目类别:
-
资助金额:$13.69万
-
财政年份:2009
-
负责人:Leslie R. Morse
-
依托单位:
Bone Density and Circulating Mediators of Bone Metabolism in Chronic SCI
-
批准号:7591815
-
项目类别:
-
资助金额:$22.66万
-
财政年份:2008
-
负责人:Leslie R. Morse
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: